Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cue Biopharma reports robust clinical data and strategic partnerships

Cue Biopharma's Q4 2022 Earnings Call highlighted strong clinical data, strategic partnerships, and upcoming milestones that position the company for growth and innovation in the biopharmaceutical sector.
While facing challenges in determining optimal registration paths and patient stratification, Cue Biopharma remains focused on leveraging opportunities through partnerships, therapeutic breakthroughs, and financial stability.
With a clear focus on advancing their pipeline, Cue Biopharma aims to drive therapeutic advancements, expand their portfolio, and establish themselves as a key player in oncology treatments.

Cue Biopharma reports strong Q2 performance and eyes transformative 2024

Cue Biopharma's Q2 2023 performance showcased revenue growth, strong cash position, and promising clinical data from trials, underlining the company's commitment to precision immunotherapy in cancer treatment.
The company's strengths in harnessing natural immune signals, achieving significant antitumor activity, and exploring rational combinations position Cue Biopharma for transformative advancements.
Challenges in decision-making, dose determination, and regulatory pathways must be navigated, but opportunities in FDA resolutions, strategic decisions, and milestone achievements abound.
With a focus on data interpretation, partnerships, and transformative therapies, Cue Biopharma is poised for an exciting and impactful 2024 with multiple milestones and growth prospects.

Cue Biopharma reports positive trial outcomes and explores strategic partnerships

Cue Biopharma's Q3 showcased strong clinical progress and financial stability.
The company's Immuno-STAT platform trials displayed promising results.
Challenges include regulatory pathways and trial expansion plans.
Opportunities lie in strategic partnerships and exploring new treatment combinations.

Cue Biopharma reports solid financials and advances in immunotherapy

Cue Biopharma's financials show steady revenue growth and prudent expense management, ensuring operational funding into 2025.
The company's strengths lie in its focused approach to developing immunotherapeutic biologics and positive trial updates in oncology and autoimmune diseases.
Challenges include strategic decision-making on partnerships, trial design, and managing trial outcome expectations based on industry data.
Opportunities exist in strategic partnerships, advancements in oncology programs, and upcoming data presentations offering insights for stakeholders.

Cue Biopharma advances autoimmune programs and partnerships for treatment innovation

Cue Biopharma's focus on autoimmune programs and strategic partnerships reflects a commitment to redefining treatment standards for cancer and autoimmune diseases. Progress with key programs and the Immuno-STAT platform demonstrates potential for targeted therapies with improved efficacy and safety. Overcoming challenges in market conditions and regulatory landscapes while seizing opportunities in program advancements and partnerships will be critical for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, provided a business and clinical progress update for the first quarter 2021.

Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?

Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Interim analysis highlights include: Confirmed partial response (PR) in one patient and stable disease (SD) in five patients, providing early signs of potential single-agent activity of CUE-101.

Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study

Cellect Biotechnology Ltd

CKX Lands

Eltek

SemiLEDs

Obalon Therapeutics

Precipio

PolarityTE Inc

Protagenic Therapeutics

Regional Health Properties

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on InvestorPlace.

Market Update: The 10 Most Volatile Stocks Today

The stock price of Cue Biopharma Inc (NASDAQ: CUE) increased by over 10% pre-market. This is why it happened.

CUE Stock: Over 10% Increase Pre-Market Explanation

And Provides Interim Clinical Data Update

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, provided a business update for the fourth quarter and full year 2020.

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.

Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021.

Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the 7 th Annual Immuno-Oncology 360° Conference on February 25, 2021.

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

Guaranty Bancshares

Harbor Custom Development, Inc.

Landec

Phillips 66

B. Riley Financial

Vector Group

Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.

7 Stocks With Insider Buying This Week Worth A Look

Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoing clinical trials (CUE-101). CUE-101 is Cue's lead therapeutic halfway through Phase 1 and targeting HPV-related cancers.

Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022

Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.

Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020.

Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, provided a business update for the third quarter of 2020.

Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020.

Cue Biopharma to Present at Upcoming Investor Conferences in November 2020

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, announced today three poster presentations highlighting the Company's clinical and pipeline progress at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020). The posters include a clinical update on CUE-101, the lead drug candidate from the IL-2 based CUE-100 series, and data supporting the potential of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform to selectively engage and modulate targeted T cells within the body in a manner that can address a broad range of indications.

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020).

News for Cue Biopharma Stock (CUE)